Christopher J. M. Whitty

Christopher J. M. Whitty

Auto-generated profile, based on publicly available information

Christopher J. M. Whitty

London School of Hygiene and Tropical Medicine, London, UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2004 in BMJ
Verified
Journal Article
Open access
PDF file
HRHugh Reyburn
Hugh Reyburn
RMRedepmta Mbatia
Redepmta Mbatia
CDChris Drakeley
Chris Drakeley
ICIlona Carneiro
Ilona Carneiro
EMEmmanuel Mwakasungula
Emmanuel Mwakasungula
CWChristopher J M Whitty
Christopher J M Whitty
Objective To study the diagnosis and outcomes in people admitted to hospital with a diagnosis of severe malaria in areas with differing intensities of malaria transmission. Design Prospective observational study of children and adults over the course a year. Setting 10 hospitals in north east Tanzania. Participants 17 313 patients were admitted to hospital; of these 4474 (2851 children aged under 5 years) fulfilled criteria for severe disease. Main outcome measure Details of the treatment given and outcome. Altitudes of residence (a proxy for transmission intensity) measured with a global positioning system. Results Blood film microscopy showed that 2062 (46.1%) of people treated for malaria had Plasmodium falciparum (slide positive). The proportion of slide positive cases fell with increasing age and increasing altitude of residence. Among 1086 patients aged ≥ 5 years who lived above 600 metres, only 338 (31.1%) were slide positive, while in children < 5 years living in areas of intense transmission (< 600 metres) most (958/1392, 68.8%) were slide positive. Among 2375 people who were slide negative, 1571 (66.1%) were not treated with antibiotics and of those, 120 (7.6%) died. The case fatality in slide negative patients was higher (292/2412, 12.1%) than for slide positive patients (142/2062, 6.9%) (P < 0.001). Respiratory distress and altered consciousness were the strongest predictors of mortality in slide positive and slide negative patients and in adults as well as children. Conclusions In Tanzania, malaria is commonly overdiagnosed in people presenting with severe febrile illness, especially in those living in areas with low to moderate transmission and in adults. This is associated with a failure to treat alternative causes of severe infection. Diagnosis needs to be improved and syndromic treatment considered. Routine hospital data may overestimate mortality from malaria by over twofold.

1 April 2005 in The Lancet
Verified
Journal Article
Closed access
BGBrian Greenwood
Brian Greenwood
KBKalifa Bojang
Kalifa Bojang
CWChristopher Jm Whitty
Christopher Jm Whitty
GTGeoffrey At Targett
Geoffrey At Targett

26 January 2007 in BMJ
Verified
Journal Article
Open access
PDF file
HRHugh Reyburn
Hugh Reyburn
HMHilda Mbakilwa
Hilda Mbakilwa
RMRose Mwangi
Rose Mwangi
OMOmbeni Mwerinde
Ombeni Mwerinde
RORaimos Olomi
Raimos Olomi
CWChristopher J M Whitty
Christopher J M Whitty
Objective To compare rapid diagnostic tests (RDTs) for malaria with routine microscopy in guiding treatment decisions for febrile patients. Design Randomised trial. Setting Outpatient departments in northeast Tanzania at varying levels of malaria transmission. Participants 2416 patients for whom a malaria test was requested. Intervention Staff received training on rapid diagnostic tests; patients sent for malaria tests were randomised to rapid diagnostic test or routine microscopy Main outcome measure Proportion of patients with a negative test prescribed an antimalarial drug. Results Of 7589 outpatient consultations, 2425 (32%) had a malaria test requested. Of 1204 patients randomised to microscopy, 1030 (86%) tested negative for malaria; 523 (51%) of these were treated with an antimalarial drug. Of 1193 patients randomised to rapid diagnostic test, 1005 (84%) tested negative; 540 (54%) of these were treated for malaria (odds ratio 1.13, 95% confidence interval 0.95 to 1.34; P=0.18). Children aged under 5 with negative rapid diagnostic tests were more likely to be prescribed an antimalarial drug than were those with negative slides (P=0.003). Patients with a negative test by any method were more likely to be prescribed an antibiotic (odds ratio 6.42, 4.72 to 8.75; P<0.001). More than 90% of prescriptions for antimalarial drugs in low-moderate transmission settings were for patients for whom a test requested by a clinician was negative for malaria. Conclusions Although many cases of malaria are missed outside the formal sector, within it malaria is massively over-diagnosed. This threatens the sustainability of deployment of artemisinin combination treatment, and treatable bacterial diseases are likely to be missed. Use of rapid diagnostic tests, with basic training for clinical staff, did not in itself lead to any reduction in over-treatment for malaria. Interventions to improve clinicians' management of febrile illness are essential but will not be easy. Trial registration Clinical trials NCT00146796.

1 August 1999 in The American Journal of Pathology
Verified
Journal Article
Closed access
KSKamolrat Silamut
Kamolrat Silamut
NPNguyen H. Phu
Nguyen H. Phu
CWChristopher Whitty
Christopher Whitty
GTGareth D.H. Turner
Gareth D.H. Turner
KLKarina Louwrier
Karina Louwrier
NWNicholas J. White
Nicholas J. White

1 March 2007 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
GHG. S. Humphreys
G. S. Humphreys
IMI. Merinopoulos
I. Merinopoulos
JAJ. Ahmed
J. Ahmed
CWC. J. M. Whitty
C. J. M. Whitty
TMT. K. Mutabingwa
T. K. Mutabingwa
RHR. L. Hallett
R. L. Hallett
The artemisinin-based combination therapies artemether-lumefantrine (AL) and amodiaquine (AQ) plus artesunate have been adopted for treatment of Plasmodium falciparum malaria in many African countries. Molecular markers of parasite resistance suitable for surveillance have not been established for any of the component drugs in either of these combinations. We assessed P. falciparum mdr1 (Pf mdr1 ) alleles present in 300 Tanzanian children presenting with uncomplicated falciparum malaria, who were enrolled in a clinical trial of antimalarial therapy. Pf mdr1 genotype analysis was also performed with isolates from 182 children who failed AQ monotherapy and 54 children who failed AL treatment. Pf mdr1 alleles 86Y, 184Y, and 1246Y were more common among treatment failures in the AQ group than among pretreatment infections. The converse was found in the AL-treated group. Children presenting with the 86Y/184Y/1246Y Pf mdr1 haplotype and treated with AQ were significantly more likely to retain this haplotype if they were parasite positive during posttreatment follow-up than were children treated with AL (odds ratio, 33.25; 95% confidence interval, 4.17 to 1441; P , <0.001). We conclude that AL and AQ exert opposite within-host selective effects on the Pf mdr1 gene of P. falciparum .

13 December 2007 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MSMATTHEW SCARBOROUGH
MATTHEW SCARBOROUGH
SGStephen B. Gordon
Stephen B. Gordon
CWChristopher J.M. Whitty
Christopher J.M. Whitty
NFNeil French
Neil French
YNYasin Njalale
Yasin Njalale
EZEduard E. Zijlstra
Eduard E. Zijlstra
In sub-Saharan Africa, bacterial meningitis is common and is associated with a high mortality. Adjuvant therapy with corticosteroids reduces mortality among adults in the developed world, but it has not been adequately tested in developing countries or in the context of advanced human immunodeficiency virus (HIV) infection. We conducted a randomized, double-blind, placebo-controlled trial of dexamethasone (16 mg twice daily for 4 days) and an open-label trial of intramuscular versus intravenous ceftriaxone (2 g twice daily for 10 days) in adults with an admission diagnosis of bacterial meningitis in Blantyre, Malawi. The primary outcome was death at 40 days after randomization. A total of 465 patients, 90% of whom were HIV-positive, were randomly assigned to receive dexamethasone (233 patients) or placebo (232 patients) plus intramuscular ceftriaxone (230 patients) or intravenous ceftriaxone (235 patients). There was no significant difference in mortality at 40 days in the corticosteroid group (129 of 231 patients) as compared with the placebo group (120 of 228 patients) by intention-to-treat analysis (odds ratio, 1.14; 95% confidence interval [CI], 0.79 to 1.64) or when the analysis was restricted to patients with proven pneumococcal meningitis (68 of 129 patients receiving corticosteroids vs. 72 of 143 patients receiving placebo) (odds ratio, 1.10; 95% CI, 0.68 to 1.77). There were no significant differences between groups in the outcomes of disability and death combined, hearing impairment, and adverse events. There was no difference in mortality with intravenous ceftriaxone (121 of 230 patients) as compared with intramuscular ceftriaxone (128 of 229 patients) (odds ratio, 0.88; 95% CI, 0.61 to 1.27). Adjuvant therapy with dexamethasone for bacterial meningitis in adults from an area with a high prevalence of HIV did not reduce mortality or morbidity. In this setting, intramuscular administration was not inferior to intravenous administration of ceftriaxone for bacterial meningitis. (Current Controlled Trials number, ISRCTN31371499.)